GRR

The State of Statins and Stents

Redbaron - The cancer issues was assessed by an independent group, it was not done by "the company". They looked at the meta analysis of the data on patients taking Vytorin to date in several large studies. That's how they came up with the "anomaly" term for what happened in the SEAS trial. It was an anomaly, based on the other data available on thousands of patients who have taken this med. Also, they (or the FDA or anyone else) can not say that there is or is not increased longevity from Vytorin because that sudy is not completed yet.